Key result
Catheter ablation for VT yields ~17% 12-month VT readmissions in ischaemic cardiomyopathy.
Why the study?
To assess the real-world characteristics and outcomes, including complications and inpatient readmissions, of commercially insured US patients undergoing catheter ablation for ischaemic or non-ischaemic VT.
Cohort (n=5,242)
Yes
Real-world data demonstrates that catheter ablation for ventricular tachycardia has a favorable safety profile, though ischaemic VT patients face notably higher 12-month readmission rates than non-ischaemic VT patients.
VT ablation shows low complications in real-world data; higher ischaemic readmissions leave optimal use open for RCTs.
BACKGROUND: Radiofrequency catheter ablation is an effective treatment to alleviate symptoms and reduce recurrent implantable cardioverter-defibrillator (ICD/CRT-D) shocks in patients with ventricular tachycardia (VT). OBJECTIVE: To assess the characteristics and outcomes (complications, inpatient readmissions) of commercially insured patients in the USA undergoing ablation for ischaemic or non-ischaemic VT. METHODS: Patients aged 18-64 years with a primary diagnosis of VT who underwent ablation between 2006 and 2015 were identified using the IBM MarketScan Commercial Database. The rate of complications including vascular complications, pericarditis, pulmonary embolism and pericardial tamponade over a 30-day post-ablation period (including index admission) was examined. Inpatient readmissions (VT-related, heart failure (HF)-related and non-VT arrhythmia-related) over the 12-month post-ablation period were examined. A Cox regression model was used to determine factors associated with inpatient readmissions. RESULTS: 5242 patients (488 with ischaemic and 4754 with non-ischaemic VT) met the study criteria. The majority of VT ablations occurred in an outpatient setting (57% for ischaemic and 66% for non-ischaemic VT). Among complications, vascular complications were most frequent (2.05% among ischaemic and 1.6% among non-ischaemic VT patients) over the 30-day post-ablation period. Among ischaemic VT patients, 17%, 7.6% and 4.7% had VT-related, HF-related and non-VT arrhythmia-related inpatient readmissions, respectively in the 12-month post-ablation period. For non-ischaemic VT patients, these numbers were 7.5%, 1.7% and 3.1%, respectively. Inpatient setting (vs outpatient), baseline ICD/CRT-D implantation, HF comorbidity and ≥2 prior hospitalisations were associated with a higher risk of post-ablation VT-related inpatient readmissions among ischaemic VT patients. Similar factors also were associated with a higher risk of post-ablation VT-related inpatient readmission among non-ischaemic VT patients. CONCLUSION: Setting of ablation and comorbidity status were found to influence readmission rates. Complication and readmission rates following VT ablation were low indicating towards the favourable safety profile of VT ablation.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2020) conducted a cohort in Ventricular tachycardia (ischaemic and non-ischaemic) (n=5,242). Catheter ablation was evaluated on VT-related inpatient readmission at 12 months (ischaemic VT cohort). Among patients undergoing catheter ablation for ventricular tachycardia, 12-month VT-related readmissions occurred in 17.01% of ischaemic VT patients and 7.49% of non-ischaemic VT patients, with low 30-day complication rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: